RARITAN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) --   Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 4 th Annual Evercore ISI HealthCONx

Strong Revenue Growth Drives Financial Results Company Raises Fiscal 2021 Guidance Across all Key Metrics Highlights   Third quarter revenue increased 15.8% to $522.5 million, or 14.3% in constant currency   Core revenue grew 14.8% to $508.9 million for the quarter, or 13.2% in constant currency  

RARITAN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its third quarter 2021 ended October 3, 2021, after the market close on Wednesday,

Company receives top customer rating across six categories in the 2021 IMV ServiceTrak™ Awards RARITAN, N.J. , Sept. 27, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics Holdings plc  (Nasdaq: OCDX) today announced that for the sixth consecutive year its Ortho Care™ Service and Support program was

New Menu Capability Now Available on VISION and VISION MAX Analyzers Increases Confidence in Blood Transfusion-Related Test Results RARITAN, N.J. , Sept. 27, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics  (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies,

RARITAN, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced the closing (the “Closing”) of the previously announced underwritten secondary offering of

RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced the pricing of the previously announced underwritten secondary offering of 22,000,000 of the

RARITAN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced that one of its shareholders (the “Selling Shareholder”), an affiliate of The Carlyle Group,

RARITAN, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in two upcoming investor conferences:

 -- Ortho's new VITROS ®  Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior COVID-19 infection.  -- Ortho is the first company to have an EUA for both a quantitative IgG